Labetalol S.A.L.F. S.P.A. Laboratorio (Labetalol Hydrochloride)

Labetalol blocks β1, β2, and α1 adrenergic receptors. β‑blockade reduces heart rate and myocardial contractility, while α1‑blockade causes peripheral vasodilation. Together these actions decrease cardiac output and systemic vascular resistance, resulting in lowered arterial pressure.

The dosage is individualized; the prescribing clinician determines the appropriate intravenous bolus or infusion rate based on the patient’s condition, blood‑pressure response, and clinical judgment. No fixed regimen is provided here.

Safety data are limited; the pregnancy category is unknown, so it should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding considerations require assessment of drug excretion in milk and maternal‑infant risk.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with selective β‑blockers, labetalol also blocks α1 receptors, offering additional vasodilation that can be advantageous in certain hypertensive emergencies. Unlike pure vasodilators, it also reduces heart rate, providing a balanced hemodynamic profile. Choice depends on the clinical scenario and patient tolerance.

The injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that has been stored outside the recommended temperature range.

Labetalol is given intravenously, either as a slow bolus injection or as a continuous infusion, according to the prescribing clinician’s instructions. The sterile solution is administered using aseptic technique, typically through an infusion pump or syringe, with careful monitoring of blood pressure and heart rate.

Serious adverse events include severe hypotension, bronchospasm, hepatic injury, heart block, and anaphylactic reactions. Patients should be monitored closely for signs of these conditions, especially during rapid intravenous administration, and immediate medical intervention should be initiated if they occur.

Labetalol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia, second‑ or third‑degree heart block, uncontrolled asthma or severe chronic obstructive pulmonary disease, and in those with cardiogenic shock. Caution is also advised in patients with hepatic impairment or diabetes.